08 September 2020: Original Paper
Prediction of Liver Prognosis from Pre-Transplant Renal Function Adjusted by Diuretics and Urinary Abnormalities in Adult-to-Adult Living Donor Liver Transplantation
Mineaki Kitamura 1ABCDEFG* , Masaaki Hidaka 2ABDE , Kumiko Muta 1BC , Satoshi Miuma 3BDE , Hisamitsu Miyaaki 3CD , Mitsuhisa Takatsuki 2D , Kazuhiko Nakao 3D , Susumu Eguchi 2DE , Hiroshi Mukae 4D , Tomoya Nishino 1ACDEDOI: 10.12659/AOT.924805
Ann Transplant 2020; 25:e924805
Table 1 Demographic data of liver transplantation recipients according to graft survival.
| Total (N=244) | Survived (N=156) | Graft loss (N=88) | P value | |
|---|---|---|---|---|
| Observational period (days) | 1689 (533–3346) | 2451 (1328–4063) | 286 (42–1225) | |
| Recipient age (years) | 54.4 (10.8) | 53.2 (11.9) | 56.6 (8.3) | 0.07 |
| Recipient sex, Male (%) | 57.8% | 55.1% | 62.5% | 0.26 |
| Recipient height (cm) | 162 (9.4) | 162 (9.5) | 161 (9.3) | 0.44 |
| Recipient weight (kg) | 63.3 (13.1) | 64.0 (13.8) | 62.0 (12.0) | 0.35 |
| Donor age (years) | 39.9 (12.8) | 37.4 (12.5) | 44.4 (12.2) | |
| Donor sex, Male (%) | 57.3% | 59.0% | 54.5% | 0.50 |
| MELD score | 18.6 (8.3) | 17.9 (7.7) | 19.9 (9.4) | 0.18 |
| Cirrhosis due to hepatitis B virus (%) | 16.0% | 17.3% | 13.6% | 0.45 |
| Cirrhosis due to hepatitis C virus (%) | 38.1% | 34.0% | 45.5% | 0.08 |
| Cirrhosis due to alcohol (%) | 14.8% | 16.0% | 12.5% | 0.45 |
| Hepatocellular carcinoma | 41.8% | 40.3% | 44.3% | 0.55 |
| Diabetes | 25.0% | 21.1% | 31.8% | 0.06 |
| Hypertension | 18.9% | 14.1% | 27.2% | 0.01 |
| Chronic kidney disease | 23.7% | 18.8% | 32.2% | 0.02 |
| Ascites (+) | 53.2% | 50.0% | 59.1% | 0.17 |
| Type 1 Hepatorenal syndrome | 2.0% | 0.6% | 4.6% | 0.04 |
| Type 2 Hepatorenal syndrome | 6.6% | 3.8% | 11.3% | 0.02 |
| Use of diuretics | 63.9% | 64.7% | 62.5% | 0.73 |
| Loop diuretics | 57.8% | 59.6% | 54.5% | 0.44 |
| Anti-aldosterone diuretics | 51.6% | 54.5% | 46.6% | 0.24 |
| Tolvaptan | 11.0% | 10.9% | 11.3% | 0.91 |
| Thiazide | 5.4% | 5.8% | 1.1% | 0.08 |
| Hemoglobin (g/dL) | 10.4 (2.2) | 10.5 (2.3) | 10.3 (2.2) | 0.55 |
| Platelets (×10) (/μL) | 80.8 (56.3) | 77.2 (53.9) | 87.1 (60.1) | 0.13 |
| Prothrombin time (%) | 52.1 (18.6) | 51.4 (17.6) | 53.2 (20.2) | 0.59 |
| Total bilirubin (mg/dL) | 7.7 (9.3) | 7.4 (9.3) | 8.2 (9.4) | 0.92 |
| Aspartate aminotransferase (IU/L) | 100 (151) | 95 (159) | 108 (135) | 0.42 |
| Alanine aminotransferase (IU/L) | 90 (184) | 87 (187) | 94 (179) | 0.82 |
| Albumin (g/dL) | 2.94 (0.58) | 2.89 (0.58) | 3.04 (0.58) | 0.046 |
| Creatinine (mg/dL) | 1.11 (1.21) | 0.89 (0.62) | 1.52 (1.78) | |
| eGFR(mL/min/1.73 m) | 72.6 (33.3) | 77.4 (31.6) | 64.0 (34.7) | 0.01 |
| Urinary abnormalities | 24.9% | 21.5% | 31.1% | 0.11 |
| Proteinuria >1+ | 9.5% | 6.3% | 15.6% | 0.02 |
| Hematuria >1+ | 21.0% | 18.2% | 26.3% | 0.17 |
| Intra-operative hemorrhage (mL) | 9801 (11674) | 8620 (7953) | 11894 (16157) | 0.35 |
| Graft volume/standard liver volume (%) | 48.6 (12.6) | 49.4 (13.4) | 47.3 (11.1) | 0.50 |
| Calcineurin inhibitors (%) | 79.7% | 91.7% | 57.6% | |
| Mycophenolate mofetil (%) | 54.8% | 61.5% | 42.3% | 0.11 |
| Data are represented as medians (interquartile ranges), percentages (%), or means (standard deviations) and collected pre- or at transplantation. MELD – model for end-stage liver disease. | ||||